Request Demo

Last update 01 Dec 2025

Oxycodone Hydrochloride

Last update 01 Dec 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Oxycodone hydrochloride (USP), Oxycodone Hydrochloride Hydrate, ATLP-02

+ [32]

Target

Opioid receptors

Action

agonists

Mechanism

Opioid receptors agonists(Opioid receptors agonists)

Therapeutic Areas

Nervous System DiseasesOther Diseases

Active Indication

Cancer PainPain

Inactive Indication

Acute PainAnalgesiaChronic Pain+ [2]

Originator Organization

Roxane Laboratories, Inc.

Active Organization

Shionogi Pharma Co., Ltd.SpecGx LLC

Purdue Pharma LP

+ [3]

Inactive Organization

Egalet Ltd.

Mallinckrodt Plc

Beijing Mengdi Pharmaceutical Co. Ltd.

+ [4]

License Organization

Protega Pharmaceuticals, LLC.

Inspirion Delivery Sciences LLC

Daiichi Sankyo, Inc.

+ [1]

Drug Highest PhaseApproved

First Approval Date

United States (26 Oct 1998),

Pain

Regulation-

Structure/Sequence

Molecular FormulaC18H22ClNO4

InChIKeyMUZQPDBAOYKNLO-RKXJKUSZSA-N

CAS Registry124-90-3

558

Clinical Trials associated with Oxycodone Hydrochloride

ChiCTR2500111841

/ Not yet recruitingNot ApplicableIIT

The median effective dose of cefoperazone combined with oxycodone for painless gastroscopy in school-age children

Start Date15 Dec 2025

Sponsor / Collaborator

The First Affiliated Hospital of Zhengzhou University

ChiCTR2500112478

/ Not yet recruitingPhase 4IIT

The Analgesic Effect of Preemptive Oxycodone at Different Doses in Thoracoscopic Surgery Patients and Its Impact on Perioperative Inflammatory Factors

Start Date01 Dec 2025

Sponsor / Collaborator-

NCT07153003

/ Not yet recruitingPhase 4IIT

Efficacy And Safety Of Tramadol And Oxycodone Versus Oxycodone Monotherapy For Pain Control After Primary Total Knee And Total Hip Arthroplasty: A Prospective Randomized Controlled Trial

The purpose of this study is to evaluate the effectiveness and safety of tramadol and oxycodone therapy in comparison to oxycodone alone as part of a multimodal pain regimen to reduce postoperative opioid consumption, pain, minimize adverse events and complications for primary total knee arthroplasty (TKA) and primary total hip arthroplasty (THA).

Start Date01 Dec 2025

Sponsor / Collaborator

Mayo Clinic

100 Clinical Results associated with Oxycodone Hydrochloride

100 Translational Medicine associated with Oxycodone Hydrochloride

100 Patents (Medical) associated with Oxycodone Hydrochloride

4,256

Literatures (Medical) associated with Oxycodone Hydrochloride

02 Nov 2025·BRITISH JOURNAL OF CANCER

Aberrant PJA2-CHRM3 signaling creates a therapeutic vulnerability in gastric tumor

Article

Author: Zhang, Ling ; Gu, Yuan ; Wang, Leihao ; Yin, Jingyi ; Huang, Liyu ; Wang, Xuefei ; Liang, Dongli ; Wang, Zhaoming ; Niu, Yinan ; Zhao, Junjie ; Li, Lingmeng ; Liu, Wenshuai ; Fu, Guoxiang ; Hua, Guoqiang

BACKGROUND:

Vagal innervation plays a pivotal role in gastric tumorigenesis and tumor progression. However, the upstream signaling regulating acetylcholine receptors (AChRs) and its contribution to carcinogenesis remains largely elusive.

METHODS:

We constructed Trp53^-/-; Cdh1^-/- mouse gastric organoids to recapitulate the morphological and functional characteristics of diffuse-type gastric cancer (DGC) for FDA-approved drug (1464 compounds) screening. We investigated the effects of AChR inhibitors in diffuse-type patient-derived organoids (PDOs) by examining IC₅₀ and xenograft tumorigenesis. Mass spectrometry and Co-immunoprecipitation was used to identify the interaction between cholinergic receptor muscarinic 3 (CHRM3) and PJA2. Ubiquitination and degradation assays were used to explore the regulation of CHRM3 by PJA2. 120 human gastric cancer specimens and GEO database were used to explore the clinical relevance of PJA2-CHRM3 signaling.

RESULTS:

mAChR inhibitors were identified as the most effective at suppressing Trp53^-/-; Cdh1^-/- organoids. Consistently, the viability of PDOs with aberrant expression of CHRM3 can be significantly inhibited by oxybutynin hydrochloride (OXY) and nortriptyline hydrochloride (NOR). Mechanistically, the RING E3 ligase PJA2 ubiquitinates and degrades CHRM3, subsequently suppressing downstream TGFβ-pSMAD3 signaling and tumor cell progression. Clinically, low PJA2 expression was correlated with high CHRM3, p-SMAD3 and choline acetyltransferase (ChAT) expression and predicted poor outcomes. Biologically, PJA2 but not its catalytically dead ΔRING mutant could suppress PDOs with aberrant CHRM3 signaling. PJA2 depletion enhanced tumor metastasis of gastric cancer cells, subsequently reversed by OXY and NOR treatment.

CONCLUSIONS:

This previously unknown PJA2-CHRM3 signaling axis provides further understanding of cholinergic innervation as well as identifies a new therapeutic vulnerability in DGC.

01 Oct 2025·PALLIATIVE MEDICINE

Oxycodone/naloxone PR versus oxycodone PR in advanced cancer: A multi-centre randomised trial (ENhANCE trial)

Article

Author: Grobler, Anneke ; Mendis, Ruwani ; Philip, Jennifer ; Le, Brian ; Wong, Aaron K

Background::

Opioid-induced constipation is a common side effect of Oxycodone. Oxycodone/Naloxone Prolonged Release (OXN PR) mitigates opioid-induced constipation in non-cancer pain, however its evidence is limited in people with pain from advanced cancer.

Aims::

To demonstrate analgesic non-inferiority, and superiority in reducing constipation for Oxycodone/Naloxone Prolonged Release (OXN PR) compared to Oxycodone Prolonged Release (Oxy PR).

Design::

Multi-centre open-label randomised controlled trial comparing OXN PR to Oxy PR over 5 weeks. The primary aim was to demonstrate analgesic non-inferiority of OXN PR compared to Oxy PR. The secondary aim was to demonstrate superiority of constipation reduction in the OXN PR arm.

Setting/participants::

Participants with moderate-severe pain (⩾4/10) from advanced cancer were eligible.

Results::

Thirty seven of planned 96 patients were recruited with the study stopping early due to enrolment challenges during the COVID-19 pandemic. Average pain was −1.5 points (95% CI −3.3; 0.4) favouring the OXN PR arm compared to Oxy PR at 5 weeks, meeting analgesic non-inferiority, defined as falling within a one point non-inferiority margin. The OXN PR arm demonstrated less constipation with a significantly lower Bowel Function Index score (−24.87 (95% CI 47.54; 2.21), p = 0.03) compared to Oxy PR. Adverse effect safety profile favoured OXN PR.

Conclusions::

OXN PR is non-inferior to Oxy PR in analgesic effectiveness and superior in reducing constipation. These results indicate OXN PR as the choice of opioid preparation in advanced cancer. Future studies may explore adding naloxone to other slow and immediate release opioid preparations.

Trial registry::

Australian New Zealand Clinical Trials Registry

Trial registration number::

ACTRN12619001282178

URL of trial registry record::

https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=377673&isReview=true

01 Oct 2025·SOCIAL SCIENCE & MEDICINE

From dealer to doctor: A case study examining how Purdue Pharma sought to leverage racial health disparities to attenuate flagging OxyContin sales

Article

Author: Banuna, Ledeebari ; Hartmann, Sanae ; Thompson, Lucy ; Lelei, Sophie ; Rosenman, Emily ; Rist, Justin ; Dolgoff, Erik ; Holmes, Louisa M ; Feng, Zixuan ; Buck, Ruth K ; Anjum, Nafisa

The objective of this study is to demonstrate ways in which Purdue Pharma and their primary consultant, McKinsey & Company, sought to leverage existing health disparities to maintain profits as the opioid epidemic worsened and regulatory pressure and negative media attention led to decreases in prescriptions of OxyContin and similar drugs. We use documents from the UCSF-Johns Hopkins Opioid Industry Documents Library, and correspondent media and policy documents, to evaluate "Project Tango," a strategy the two companies devised between 2014 and 2015 to enter the substance use disorder treatment market and expand sales to new customers. We find that Project Tango was one part of a broader strategy by Purdue Pharma to adapt and profit from the existing landscape of structural racism in medical care by investing more in drug sales and targeting medically underserved patients, particularly Black and Latino populations, and those enrolled in Medicaid. We contextualize the results to underline the importance of processes of structural racism to segmenting the pain management and substance use treatment markets in a manner that sought to capitalize on the very racism that prevented Asian, Black, Indigenous and Latino patients from obtaining pharmaceutical relief in the earlier days of the epidemic. We conclude that, (1) in absence of stronger federal regulation, especially in light of the recent reversal of the Chevron doctrine, local and state regulatory policies have found considerable success in limiting pharmaceutical excess, and policy at subnational levels will continue to be essential as the opioid epidemic still rages; and (2) greater use of resources such as the opioid industry documents can provide novel insight into processes of structural racism and offer targets for counter-intervention strategies.

227

News (Medical) associated with Oxycodone Hydrochloride

20 Nov 2025

·ir.ensysce.com

Ensysce Biosciences Receives Positive FDA Feedback on PF614 Manufacturing Approach

~ FDA Response Streamlines Path to Commercial Production of PF614~ SAN DIEGO, CA / ACCESS Newswire / November 20, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering next-generation pain and central nervous system therapeutics designed to minimize abuse and overdose risk, today announced that the Food and Drug Administration (FDA or Agency) provided Written Responses to a meeting request. Ensysce had requested guidance on its approach to the manufacture of PF614, wanting to understand the appropriateness of regulatory starting materials (RSMs) and specifications for PF614 drug substance and the RSMs. In its written responses, the Agency agreed with all of Ensysce's proposed plans. These responses provide Ensysce with a direct path to commercial production of PF614, which is currently being initiated with its manufacturing partner, Purisys, LLC, a subsidiary of Noramco, LLC. Dr. Jeff Millard, Chief Operating Officer of Ensysce who lead the CMC effort stated "We are extremely pleased with the FDA's feedback, which validates our approach and enables us to accelerate PF614's path to market. This milestone brings us closer to providing safer pain relief options for patients in need." "The feedback from the FDA now provides us with a clear path to scaling our manufacture of PF614 for its commercial production," said Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce. "PF614 is our TAAP™ oxycodone analogue and the leading product in our Next Generation Analgesic pipeline of TAAP™ and MPAR® products. We are exceptionally pleased that our meeting package was so well received and that we are aligned with the FDA requirements for producing this novel therapeutic that is designed to alleviate moderate to severe pain while providing what we believe are safer qualities for the general public who require this level of pain relief." About Ensysce Biosciences Ensysce Biosciences is a clinical-stage company with a goal of disrupting the analgesic landscape by introducing a new class of highly novel opioids for the treatment of severe pain. Leveraging its Trypsin-Activated Abuse Protection (TAAP™) and Multi-Pill Abuse Resistance (MPAR®) platforms, the Company is developing unique, tamper-proof treatment options for pain that minimize the risk of both drug abuse and overdose. Ensysce's products are anticipated to provide safer options to treat patients suffering from severe pain and assist in preventing deaths caused by medication abuse. For more information, please visit www.ensysce.com. Forward-Looking Statements Statements contained in this press release that are not purely historical may be deemed to be forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Without limiting the foregoing, the use of words such as "may," "intends," "can," "might," "will," "expect," "plan," "possible," "believe" and other similar expressions are intended to identify forward-looking statements. The product candidates discussed are in clinic and not approved and there can be no assurance that the clinical programs will be successful in demonstrating safety and/or efficacy, that Ensysce will not encounter problems or delays in clinical development, or that any product candidate will ever receive regulatory approval or be successfully commercialized. All forward-looking statements are based on estimates and assumptions by Ensysce's management that, although Ensysce believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Ensysce expected. In addition, Ensysce's business is subject to additional risks and uncertainties, including among others, possible NASDAQ delisting, the initiation and conduct of preclinical studies and clinical trials; the timing and availability of data from preclinical studies and clinical trials; expectations for regulatory submissions and approvals; potential safety concerns related to, or efficacy of, Ensysce's product candidates; the availability or commercial potential of product candidates; continuation of government funding; the ability of Ensysce to fund its continued operations, including its planned clinical trials; the dilutive effect of stock issuances from our fundraising; and Ensysce's and its partners' ability to perform under their license, collaboration and manufacturing arrangements. These statements are also subject to a number of material risks and uncertainties that are described in Ensysce's most recent quarterly report on Form 10-Q and current reports on Form 8-K, available free of charge at the SEC's website at www.sec.gov. Any forward-looking statement speaks only as of the date on which it was made. Ensysce undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required under applicable law. Ensysce Biosciences Company Contact: Lynn Kirkpatrick, Ph.D. Chief Executive Officer (858) 263-4196 Ensysce Biosciences Investor Relations Contact: Shannon Devine MZ North America Main: 203-741-8811 ENSC@mzgroup.us SOURCE: Ensysce Biosciences Inc. Released November 20, 2025

18 Nov 2025

·www.fiercepharma.com

Sackler family, Purdue Pharma's $7.4B settlement plan wins bankruptcy judge's approval

U.S. Bankruptcy Judge Sean Lane signed off on the deal on Tuesday after it earned "remarkable consensus" from creditors, according to Purdue. After a legal saga involving thousands of civil lawsuits, a Supreme Court ruling and what was once one of America’s wealthiest families, a U.S. bankruptcy judge has signed off on the $7.4 billion settlement that will close the books on the opioid crisis litigation surrounding Purdue Pharma and its former owners, the Sackler family. U.S. Bankruptcy Judge Sean Lane of the U.S. Bankruptcy Court in the Southern District of New York formally signed off on the plan on Tuesday, mandating the Sacklers to pay up to $7 billion over 15 years, the AP reported. The majority of the money will go to government entities to combat the opioid crisis locally, while a pool of about $850 million designated for individual victims will be distributed next year. Overall, at least $7.4 billion will be doled out to Purdue’s public and private creditors, settlement mediator Willkie Farr & Gallagher explained in an announcement. An additional $500 million could come from the sale of the Sacklers’ international pharmaceutical business. Added cash recoveries are also expected from insurance and other litigation, Purdue said in a Nov. 14 release.“My heart goes out to all those who have suffered such pain,” Lane said in approving the plan, as quoted by AP. “The settlements are fair and equitable and in the best interest of the bankruptcy estates.”The bankruptcy plan achieved a “remarkable consensus” from voting creditors, with more than 99% support, Purdue Pharma pointed out in its release. Purdue issued the release after the court indicated it would approve the plan following a confirmation hearing that involved more than 5,000 pages of testimony and dozens of witnesses.“The Plan is the product of intense work with our creditors through a singular, shared focus on delivering as much value as possible to meaningfully address the opioid crisis,” Purdue board chairman Steve Miller said in a statement. “We are grateful for the perseverance and herculean efforts of our creditors who worked with us to craft an entirely consensual plan that unlocks billions in recoveries and significant non-monetary benefits.”With that, Purdue Pharma will be no more. The company filed for bankruptcy in 2019 after accruing a mountain of litigation for its marketing of opioid-based painkiller OxyContin, a major factor in the nationwide opioid crisis.Purdue’s Chapter 11 bankruptcy reorganization plan dissolves Purdue and transfers its assets to a newly formed company called Knoa Pharma. Knoa will be owned by an independent foundation and provide millions of doses of opioid use disorder treatments and overdose reversal meds with “no obligation to maximize profits,” according to Purdue.The Sacklers haven’t had formal involvement with Purdue for years, with the last member of the Sackler family to sit on the company’s board stepping down at the start of 2019. The family will continue to have “no interest or role in” the new company, which will be subject to a “strict operating injunction” and overseen by a monitor to ensure it provides its products safely, according to the plan.The plan also mandates a document repository that exposes millions of documents related to Purdue’s historical sales and marketing practices. Purdue was required to emerge from its bankruptcy as a public benefit company by the U.S. Justice Department in 2020, when Purdue agreed to plead guilty to felony charges tied to its misleading OxyContin marketing. Since then, the company has been making efforts to restore its public image. Last year, it won an FDA approval for its emergency opioid overdose rescue treatment Zurnai, an nalmefene injection.The Sacklers, meanwhile, previously came out of years of negotiations with a proposed $6 billion settlement that would have granted them legal immunity from civil lawsuits. That plan went through numerous courts before being knocked down by the U.S. Supreme Court, which determined that the Sacklers, who had not themselves filed for bankruptcy, weren’t eligible for protection from current and future litigation.The new, now-confirmed bankruptcy settlement is the largest U.S. opioid related settlement with individuals to date. Other billion-dollar settlements have come from drugmakers and drug distributors also involved in the opioid crisis, such as Johnson & Johnson, AmerisourceBergen, Cardinal Health and McKesson’s $26 billion deal in 2022 or Teva’s $4.25 billion settlement in the same year.

Patent Infringement

10 Sep 2025

·www.einpresswire.com

FDA Issues New Guidance to Expand Non-Opioid Options for Chronic Pain, Curb Misuse

For Immediate Release: September 10, 2025 Despite recent declines, opioids remain commonly prescribed to about 1 in 5 U.S. adults who live with chronic pain as effective alternatives are limited. As part of its broader strategy to address the opioid crisis, the U.S. Food and Drug Administration today issued draft guidance titled “Development of Non-Opioid Analgesics for Chronic Pain” to accelerate safe and effective non-opioid treatments and to reduce prescription-related opioid misuse. The new draft guidance emphasizes efficient drug development approaches, with specific attention to trial design, appropriate patient populations, and meaningful outcomes- such as reducing the need for opioid use. “America’s opioid crisis is not over. We must stay vigilant to address this longstanding problem in new ways. Physicians need more alternatives to opioid medications for patients suffering from chronic pain,” said FDA Commissioner Marty Makary, M.D., M.P.H. “FDA can help by providing clear guidance like this, which makes regulatory pathways more predictable for innovators and drug developers, enabling effective, lower-risk therapies to quickly reach the millions of Americans living with chronic pain.” The draft guidance outlines regulatory considerations related to: Establishing indications for different scopes (e.g., broader categories covering multiple chronic pain conditions versus individual chronic pain indications); Designing clinical trials that ensure robust evaluation of safety and efficacy, including innovative trial designs and the role of mechanistic understanding of both the drug and the chronic pain conditions being treated; Evaluating the ability of non-opioid drugs to avoid, reduce, or eliminate opioid use; and Incorporating statistical principles, patient-reported outcomes, and the use of expedited programs to support drug development in this area. The guidance fulfills a mandate under Section 3001(b) of the SUPPORT Act , which requires the FDA to issue guidance to help address challenges related to developing non-opioid treatments for pain management. The FDA’s broader strategy to address the opioid crisis includes requiring safety labeling changes for opioid pain drugs (e.g., OxyContin) to better reflect current evidence; enhancing enforcement around the importation and sale of illegal opioid products; and facilitating the development of non-opioid alternatives. The FDA is encouraging the public to comment on this draft guidance. Stakeholders have 60 days from the date of publication in the Federal Register to submit feedback electronically at www.regulations.gov or in writing to the Dockets Management Staff, referencing FDA-2025-D-0610 in the Federal Register notice. Related Information ### Boilerplate The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, radiation-emitting electronic products, and for regulating tobacco products. Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

100 Deals associated with Oxycodone Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D00847	Oxycodone Hydrochloride	N02AA05	DBSALT000277

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Cancer Pain	Japan	Shionogi Pharma Co., Ltd.	01 May 2012
Acute Pain	China	Bard Pharmaceuticals Ltd.	21 Jan 2004
Chronic Pain	China	Bard Pharmaceuticals Ltd.	21 Jan 2004
Pain	United States	Roxane Laboratories, Inc.	26 Oct 1998

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Low Back Pain	Phase 3	United States	Egalet Ltd.	01 Mar 2016
Osteoarthritis, Spine	Phase 3	United States	Purdue Pharma LP	01 Apr 2004
Analgesia	Phase 1	United States	Purdue Pharma LP	01 Jul 2010
Analgesia	Phase 1	Australia	Purdue Pharma LP	01 Jul 2010
Analgesia	Phase 1	Finland	Purdue Pharma LP	01 Jul 2010
Analgesia	Phase 1	New Zealand	Purdue Pharma LP	01 Jul 2010

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05974501 (CTgov)	Phase 4	complications of arthroplasty \| Osteoarthritis, Knee \| Pain, Postoperative	84	Lyrica+Ropivacaine+Acetaminophen+Oxycodone+Dexamethasone+Celebrex+Meloxicam (Preoperative Adductor Canal Block Group)	rohcocnikb(yrqwsdmrix) = ssfvvkhkjk fkpdkjqizt (fobmcjwdxx, wmzaamtqej - gmbopqtcjw) View more	-	12 Feb 2025
				Lyrica+Ropivacaine+Acetaminophen+Oxycodone+Dexamethasone+Celebrex+Meloxicam (Postoperative Adductor Canal Block Group)	rohcocnikb(yrqwsdmrix) = uqjctafmom fkpdkjqizt (fobmcjwdxx, lvzwqnuyur - hgixandyyr) View more
NCT01458015 (CTgov)	Phase 4	Neuralgia	3	oxycodone+tapentadol (Oxycodone)	rwrmqjskpc(xqkjcdqfjt) = rkjelfodpu coryqjpkks (uyzxqxjjkj, imjvdcqnch - olnlmvdfjl) View more	-	17 Dec 2024
				oxycodone+tapentadol (Tapentadol)	rwrmqjskpc(xqkjcdqfjt) = mdbwzkhkbt coryqjpkks (uyzxqxjjkj, zejuduzjda - fglsumyjpz) View more
NCT03859024 (CTgov)	Phase 4	Urethral Stricture \| Pain, Postoperative	48	Acetaminophen+Oxycodone+Ibuprofen 800 mg (Standard Protocol)	oivraqyafi(zlhmtrxdbl) = effndijgst xdbnbexzus (wwjnqjjqfd, tmspjezrhk - zpaayyiuoy) View more	-	19 Sep 2024
				Acetaminophen+Oxycodone+Dexamethasone+Ibuprofen 800 mg+Bupivacaine+celebrex+Gabapentin (Enhanced Recovery Protocol)	oivraqyafi(zlhmtrxdbl) = smglsegyea xdbnbexzus (wwjnqjjqfd, buixqlhqpb - snhwlacunj) View more
NCT04791761 (CTgov)	Phase 1/2	Pain, Postoperative	73	Opioid disposal education+Acetaminophen+Oxycodone+Ibuprofen (Opioid Pain Control)	wmaeotthzi(lpyjnqdfms) = grlqlgyahv sdhslknovp (vvoctgguhu, vpfndcxfmo - sdltkkejvn) View more	-	16 Aug 2024
				Acetaminophen+Ibuprofen (Non-opioid Pain Control)	wmaeotthzi(lpyjnqdfms) = usbkfwujqc sdhslknovp (vvoctgguhu, ucxapzblxy - ztaejypgpp) View more
NCT04015908 (CTgov)	Phase 4	-	100	Pregabalin+Acetaminophen+Oxycodone+celecoxib (Multi-modal)	zunbktoqcx(gzcozdbvvz) = pfafuipkpe nipmqtdpih (eayainniiy, hmxgpevbnh - jererrwivj) View more	-	08 Jul 2024
				Percocet (Control)	zunbktoqcx(gzcozdbvvz) = cckrqtzbns nipmqtdpih (eayainniiy, bvqhqmaubd - czqmvjxjnd) View more
NCT03612713 (CTgov)	Early Phase 1	Drug abuse	20	Oxycodone (Oxycodone Run)	hbianljazd(hjaitgsvry) = zopziztaqu bjcdklrprj (sncwczyuoy, 1.37) View more	-	08 Mar 2024
				placebo (Placebo Run)	hbianljazd(hjaitgsvry) = tjgfixzcjc bjcdklrprj (sncwczyuoy, 2.46) View more
NCT04122443 (CTgov)	Phase 4	Musculoskeletal Pain	393	Acetaminophen+Ibuprofen (Ibuprofen and Then Acetaminophen (Stage 2))	rbclrpfjtn(yhzupdlxzl) = iizrbrgnoq pmtixttqpd (khasgdwcwf, 2.4) View more	-	28 Feb 2024
				Acetaminophen+Oxycodone+Ibuprofen (Ibuprofen and Then Oxycodone/Acetaminophen (Stage 2))	rbclrpfjtn(yhzupdlxzl) = lfmltslaqs pmtixttqpd (khasgdwcwf, 2.6) View more
NCT04285853 (CTgov)	Phase 4	Anterior Cruciate Ligament Injuries	98	Oxycodone (Oxycodone Arm)	kadkxgfooc(ewxcwqiija) = fkrbmyzedv gfdsqsttzq (iactyxwuhz, nivgbmmawy - zhphvlcjve) View more	-	11 Oct 2023
				Placebo oral tablet (Placebo Arm)	kadkxgfooc(ewxcwqiija) = whoxoddljj gfdsqsttzq (iactyxwuhz, nzhtttjgoq - mxsyyaykdo) View more
NCT04149964 (CTgov)	Phase 4	Fistula \| Pain, Postoperative	65	Acetaminophen/Hydrocodone 325 mg/7.5 mg oral tablet+Acetaminophen 325 mg Oral Tablet (Standard of Care Arm)	gwenseiuhi(bhzheedycz) = xgqlukzhey ftsunziqtw (mneceltito, vzpqlrzvdq - juhyxxnjet) View more	-	31 Aug 2023
				Acetaminophen 650 mg Oral Tablet+OxyCODONE 5 mg Oral Tablet (Study Arm)	gwenseiuhi(bhzheedycz) = vanyuotbmw ftsunziqtw (mneceltito, tljhiwonbj - oqdgkcppcp) View more
NCT05053126 (CTgov)	Phase 4	-	60	Placebo (Placebo)	qbydcasfvz(itsrvdqrek) = ybnulzqlza nsairsyewh (ettboheakr, 1.786) View more	-	14 Aug 2023
				oxycodone 20 mg (Oxycodone 20 mg)	qbydcasfvz(itsrvdqrek) = ivvyttvdos nsairsyewh (ettboheakr, 2.493) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis